Navigation Links
Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 Diabetes
Date:9/20/2010

PARIS, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

"These results demonstrated lixisenatide as a once daily GLP-1 agent with substantial A1C reduction and a pronounced effect on post-meal glucose control," said Dr. John E. Gerich of the University of Rochester School of Medicine and an investigator of the presented study. "The pronounced effect on postprandial glucose control provides a rationale to investigate the combined effect of lixisenatide and long-acting insulins in patients with type 2 diabetes."

The safety and efficacy of lixisenatide as monotherapy in patients with type 2 diabetes was assessed in a 12-week, randomized, double-blind, multicenter Phase III study. The study found that lixisenatide monotherapy administered once daily significantly improved glycemic control with a pronounced postprandial effect. The study also demonstrated that the therapy had an acceptable safety profile in patients with type 2 diabetes.

A total of 361 patients with type 2 diabetes (baseline A1C levels: 7 to 10 percent, mean age 53.7 years, mean diabetes duration 2.5 years) not currently receiving glucose-lowering therapy were randomized to: lixisenatide two-step titration (10 microgram for 1 week, 15 microgram for 1 week then 20 microgram; n=120); lixisenatide one-step titration (10 microgram for 2 weeks then 20 microgram; n=119) or placebo (n=122).

Lixisenatide significantly reduced A1C levels in both titration groups versus placebo (p<0.0001). There was a significa
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. 24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
2. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
3. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
4. Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting
5. Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be Presented at Major Medical Meeting
6. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
7. Abbotts Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
8. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
9. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
10. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
11. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... 30, 2015 IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, August 6, 2015 ... business developments. Interested parties may access the ...
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... 2011 Total quarterly revenues of ... grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel ... of $0.34 versus $0.46 for prior year ... from 2010 Company reaffirms 2011 guidance ...
... Ohio, Oct. 27, 2011 Cardinal Health today reported ... an 11 percent increase in non-GAAP diluted earnings per ... EPS from continuing operations declined 19 percent to $0.68, ... of CareFusion stock. Strong revenue growth was driven by ...
Cached Medicine Technology:Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 3Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 4Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 5Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 6Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 7Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 8Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 9Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 10Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 11Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 12Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 13Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 14Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 15Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 16Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 17Cardinal Health Reports First-Quarter Results 2Cardinal Health Reports First-Quarter Results 3Cardinal Health Reports First-Quarter Results 4Cardinal Health Reports First-Quarter Results 5Cardinal Health Reports First-Quarter Results 6Cardinal Health Reports First-Quarter Results 7Cardinal Health Reports First-Quarter Results 8Cardinal Health Reports First-Quarter Results 9Cardinal Health Reports First-Quarter Results 10Cardinal Health Reports First-Quarter Results 11Cardinal Health Reports First-Quarter Results 12Cardinal Health Reports First-Quarter Results 13Cardinal Health Reports First-Quarter Results 14Cardinal Health Reports First-Quarter Results 15Cardinal Health Reports First-Quarter Results 16Cardinal Health Reports First-Quarter Results 17Cardinal Health Reports First-Quarter Results 18
(Date:7/31/2015)... ... , ... There’s no better way to enjoy the summer weather than by ... next meal, making July the most appropriate to be National Hot Dog Month. King ... Make the next cookout different than the ones in the past. Celebrate National Hot ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries and delicious ... with custom designs, making life just a little bit sweeter for newlyweds. A ... each customer who orders one. , The bakery provides a full line of custom ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... one-day event geared to patients and family members, medical professionals, and researchers, covering ... mesothelioma experts. The conference is a collaborative effort between the Mesothelioma Applied Research ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... will help treat baldness by growing new hair follicle cells//. ... hair follicles from the back of the neck, multiplying them ... BBC News. ,It initially tested the treatment on ... hair. They are to test the treatment on 20 more ...
... group of pioneering psychiatrists who worked in Saskatchewan, Canada in ... Dyck, who is working on it for the last 5 ... the University of Alberta, sited records of the psychiatrists' research, ... single dose of the hallucinogenic drug LSD, administered in a ...
... A team of scientists from the University of Adelaide, ... world breakthrough in understanding how bacterial toxins cause// severe ... Adrienne Paton from the University of Adelaide’s School of ... potent bacterial toxin kills cells by inactivating an essential ...
... Paswan promises a new policy for the poor that will ... tuberculosis, AIDS and cancer. ,"By Jan 1 we ... will offer free medication to the poor," Paswan said in ... with the help of the drug manufacturers who have agreed ...
... surgeons at The Methodist Hospital shows unprecedented improvements in ... Lucentis? for wet// age-related macular degeneration (AMD), according to ... Medicine. AMD is a major cause of central visual ... blindness in people over 60. ,Dr. David ...
... revealed that behavioral therapies can benefit children who have problems ... ,The American Academy of Sleep Medicine (AASM) appointed a ... babies and toddlers. ,According to study author Jodi ... have shown 20 to 30 percent of young children have ...
Cached Medicine News:Health News:Effective Cure for Alcoholism – A single dose of LS 2Health News:Effective Cure for Alcoholism – A single dose of LS 3Health News:Scientists Make World Breakthrough 2Health News:Free Medicines, Health Insurance for Poor Soon: Paswan 2Health News:Results for Wet Age-Related Macular Degeneration Show Significant Vision Improvements 2
Inquire...
... More than 1 million people are ... a majority of these patients never seek ... The TRIVEX* System can offer them an ... vein removal, (stab avulsion or hook phlebectomy), ...
...
... of experience, the SSD-1000 is a high ... uses our advanced technologies and over 5 ... same technology as our more expensive systems, ... a compact and mobile setting., We also ...
Medicine Products: